ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 2598 • ACR Convergence 2024

    p300 KAT Inhibition Selectively Targets Multiple Cell Types Involved in Chronic Inflammation and Downregulates Key Inflammatory Cytokines

    Zhihua Ma, Luis Carvajal, Andrew Chen, Rosa Villagomez, Yare calderon, Tamara Hopkins, Hua Gao, Benjamin Trotter, Charles Lin and Peter Rahl, Kronos Bio, Cambridge, MA

    Background/Purpose: Across inflammatory and autoimmune diseases, pathologic signaling converges in the nucleus to elevate transcription of numerous inflammatory effectors such as cytokines, chemokines and antibodies.…
  • Abstract Number: 2473 • ACR Convergence 2024

    Criterion Validity of Modified Rodnan Skin Score: Does It Capture Skin Thickness or Hardening? Results of a Large Skin Histology Study

    Shervin Assassi1, Ruhani Desai2, Jeffrey Browning3, Samuel Theodore1, Meng Zhang1, Brian Skaug1, Jerry Alonso1, Zsuzsanna McMahan1, Maureen Mayes1 and Minghua Wu1, 1UTHealth Houston Division of Rheumatology, Houston, TX, 2UTHealth Houston Division of Rheumatology, DeLand, FL, 3Boston University, Cambridge, MA

    Background/Purpose: Modified Rodnan Skin Score is a widely used outcome measure for skin involvement in systemic sclerosis (SSc). Its criterion validity (comparison to the gold…
  • Abstract Number: 2682 • ACR Convergence 2024

    The Forgotten Costs of SLE: Estimating Indirect Costs in a National SLE Cohort

    Ann E. Clarke1, Yvan St-Pierre2, Megan Barber1, Sasha Bernatsky3, Evelyne Vinet4, Christian Pineau5, Murray Urowitz6, Dafna Gladman7, Christine Peschken8, John Hanly9, Alexandra Legge10 and Paul Fortin11, 1Division of Rheumatology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, 2McGill University Health Center, Montreal, QC, Canada, 3Research Institute of the McGill University Health Centre, Montreal, QC, Canada, 4McGill University Health Centre, Montreal, QC, Canada, 5McGill University, Montreal, QC, Canada, 6Self employed, Toronto, ON, Canada, 7University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 8University of Manitoba, Winnipeg, MB, Canada, 9Dalhousie University, Halifax, NS, Canada, Halifax, NS, Canada, 10Dalhousie University, Halifax, NS, Canada, 11Centre ARThrite - CHU de Québec - Université Laval, Quebec, QC, Canada

    Background/Purpose: Economic analyses of SLE often include only direct healthcare costs.  Indirect costs, particularly those attributable to lost productivity in unpaid labour, are often overlooked,…
  • Abstract Number: 2686 • ACR Convergence 2024

    Dose Escalation Safety Study of Brentuximab Vedotin for Diffuse Cutaneous Systemic Sclerosis:Clinical Results and Mechanistic Analysis of Skin and Peripheral Blood Mononuclear Cells

    David Fox1, Laura Cooney2, Lia Stelzig3, Robert Lafyatis4, Johann Gudjonsson5, Lam Tsoi6, Maureen Mayes7, Ankoor Shah8, Suzanne Kafaja9, William Barry3, Ellen Goldmuntz10, Dawn Smilek11 and Dinesh Khanna6, 1University of Michigan, Dexter, MI, 2University of Michigan and Immune Tolerance Network, Ann Arbor, MI, 3Rho, Durham, NC, 4Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, 5Department of Dermatology, University of Michigan, Ann Arbor, MI, 6University of Michigan, Ann Arbor, MI, 7UTHealth Houston Division of Rheumatology, Houston, TX, 8Duke University, Durham, NC, 9Division of Rheumatology, University of California, Los Angeles, Los Angeles, CA, 10Division of Allergy, Immunology, and Transplantation, National Institute of Allergy and Infectious Diseases, Rockville, MD, 11Immune Tolerance Network, UCSF, San Francisco, CA

    Background/Purpose: Brentuximab vedotin (ADCETRIS®) is a drug antibody conjugate targeting CD30 approved for treatment of Hodgkin’s lymphoma (HL) and other hematologic malignancies. Association of CD30…
  • Abstract Number: 2687 • ACR Convergence 2024

    Therapeutic Choices in Systemic Sclerosis Associated Interstitial Lung Disease, a Survey of International Experts

    Michael Macklin1, Iazsmin Bauer Ventura1 and Dinesh Khanna2, 1University of Chicago, Chicago, IL, 2University of Michigan, Ann Arbor, MI

    Background/Purpose: The therapeutic options for systemic sclerosis-associated interstitial lung disease (SSc-ILD) have evolved rapidly, with recent guidelines released by the ACR and American Thoracic Society…
  • Abstract Number: 2657 • ACR Convergence 2024

    Prevalence of Anxiety, Depression, and Fatigue in Patients with Rheumatic Diseases: A Cross-Sectional Study of 1014 Cases

    Gabriela Anais Madrid-Lopez1, Maria Corral-Trujillo2, Amado Arturo Diaz-Guerrero3, Luisa Fernanda Mata-Torres3, Eva Galindo Calvillo4, Jesus Cardenas-de la Garza2, Ivan Hernandez Galarza5, Miguel Angel Villarreal-Alarcon6 and Dionicio Galarza-Delgado7, 1Facultad de Medicina, Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico, 2Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico, 3Universidad Autónoma de Nuevo León, Monterrey, Mexico, 4Universidad Autónoma de Nuevo León, Saltillo, Coahuila, Mexico, 5University Hospital, UANL, San Pedro Garza Garcia, Nuevo León, Mexico, 6Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, 7UANL Hospital Universitario, Monterrey, Nuevo León, Mexico

    Background/Purpose: Individuals diagnosed with rheumatic diseases (RD) have an elevated susceptibility to mental health disorders. A study conducted among patients with RD revealed a prevalence…
  • Abstract Number: 2601 • ACR Convergence 2024

    Platelets Specifically Interact with Remigrating Neutrophils and Promote Immunogenic Cellular Death in Systemic Lupus

    Marie nansion1, Eloi Schmauch2, Pierre Vacher3, Jean Sibilia4, Nathan Broussaudier1, Adeline Bruchon1, Pierre Grenot1, Anne-Sophie Korganow5, Thierry Martin5, Sophie Caillard6, Anna Duval6, Jacques-Eric Gottenberg7, Raphaël Carapito1, Séiamak Bahram1, Patrick Blanco8 and Marc Scherlinger9, 1UMR_INSERM 1109, Strasbourg, France, 2Broad Institute of MIT and Harvard, Cambridge, MA, USA., Boston, MA, 3Inserm U1045, Bordeaux, France, 4Strasbourg University Hospital, National reference center for autoimmune disease, Rheumatology, Strasbourg, France, 5Strasbourg University Hospital, National reference center for autoimmune disease, Clinical Immunology, Strasbourg, France, 6Nephrology department, HUS, Strasbourg, France, 7Rheumatology Department, Strasbourg University Hospital,, Strasbourg, France, 8UMR_CNRS 5164 Immunoconcept, BORDEAUX CEDEX, France, 9Strasbourg University Hospital; INSERM 1109, Strasbourg, France

    Background/Purpose: In SLE, platelet activation (express P-selectin+) follows the disease activity, which plays a role in thrombosis as well as in inflammation (1). Neutrophils express high levels of PSGL-1,…
  • Abstract Number: PP03 • ACR Convergence 2024

    How Completing a Systematic Literature Review Improved How I Research My Own Rheumatoid Arthritis and Comorbidities

    Shelley Fritz, Global Healthy Living Foundation, Kalaheo, HI

    Background/Purpose: Twelve years ago, I was diagnosed with rheumatoid arthritis (RA). Initially, I was hopeful that the first biologic DMARD would slow the disease and…
  • Abstract Number: PP04 • ACR Convergence 2024

    Involving Pediatric Patients in Their Own Care

    Whitney LaBar, Lupus and Allied Diseases Association, Pleasanton, CA

    Background/Purpose: When I was 14, I was diagnosed with thrombocytopenia, which led to more testing and a diagnosis of systemic lupus erythematosus (SLE). As a…
  • Abstract Number: 2612 • ACR Convergence 2024

    Two-Week Methotrexate Discontinuation in Autoimmune Rheumatic Diseases Patients Vaccinated with Recombinant Herpes Zoster Vaccine: An Interim Analysis of a Prospective Randomized Phase 4 Study

    Ana Cristina Medeiros-Ribeiro1, Joao de Oliveira2, Nadia Aikawa3, Sandra Pasoto2, Leonard Kupa2, Carla Goncalves Schahin Saad4, Luciana Parente2, ANA PAULA ASSAD2, Eduardo Borba2, Emily Figueiredo Neves Yuki2, Andrea Shimabuco4, Karina Bonfiglioli2, Diogo Domiciano2, Percival Sampaio-Barros4, Andre Franco2, Julio Moraes5, Murillo Dorio2, Claudia Goldenstein-Schainberg2, Henrique Carriço Da Silva2, Lucas Guimarães2, Fernanda Chaer6, Caio Laguna Reis de Carvalho2, Henrique Dalmolin2, Clovis Silva7 and Eloisa Bonfa2, 1Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Jose Dos Campos, Brazil, 2Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, SP, Brazil, 3Rheumatology Division and Pediatric Rheumatology Unit, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil, 4Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, SP, Brazil, 5Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Jundiai, Brazil, 6Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Santos, Brazil, 7Rheumatology Division and Pediatric Rheumatology Unit, Instituto da Criança e do Adolescente, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, SP, Brazil

    Background/Purpose: Temporary methotrexate (MTX) discontinuation may enhance vaccine immune response, but there are no data for the recombinant zoster vaccine (RZV). This study assessed if…
  • Abstract Number: PP08 • ACR Convergence 2024

    Whispers of Resilience: Navigating Life with Rheumatism

    Vinchelle Hardison and Vinchelle Hardison, Nationwide Children's Hospital, Columbus, OH

    Background/Purpose: “What’s wrong with me mom? Why am I always slow and hurting? Why can’t I play without being in pain like the other kids?”…
  • Abstract Number: 2506 • ACR Convergence 2024

    THP1-derived Macrophage Polarization in Takayasu Arteritis – Impact of Disease Status and Therapy

    João Paulo dos Santos1, Cristina Orikaza1, Mariana Aguiar2, Gerson Keppeke3 and Alexandre de Souza4, 1Universidade Federal de Sao Paulo, São Paulo, SP, Brazil, 2Rheumatology Division, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, SP, Brazil, 3Universidad Catolica del Norte, São Paulo, Coquimbo, Brazil, 4UNIFESP-EPM, São Paulo, SP, Brazil

    Background/Purpose: Macrophages play an important role in the pathophysiology of Takayasu arteritis (TAK) as granulomatous inflammation is typically found in affected arteries. The expression of…
  • Abstract Number: 2684 • ACR Convergence 2024

    Assessment of Skin in Patients with Systemic Sclerosis Using High Frequency Ultrasound : A Comparative Study with Histology and Clinical Parameters of Skin Disease

    Ruhani Desai1, Filemon Tan2, Minghua Wu3, Jefferey Browning4, Samuel Theodore3, Meng Zhang3, Brian Skaug3, Maureen Mayes3 and Shervin Assassi3, 1UTHealth Houston Division of Rheumatology, DeLand, FL, 2University of Texas at Houston McGovern Medical School, Houston, TX, 3UTHealth Houston Division of Rheumatology, Houston, TX, 4Boston Univeristy, Boston, MA

    Background/Purpose: The extent of skin involvement and its rate of progression can provide prognostic information for systemic sclerosis (SSc)-related morbidity and mortality. Moreover, skin assessment…
  • Abstract Number: 2631 • ACR Convergence 2024

    Risk of Atherosclerotic Cardiovascular Events and Venous Thromboembolism in People with Primary Sjögren’s Syndrome: A Danish Cohort Study

    Pierre Loiseau1, Aurélie Mailhac2, Pierre Duhaut1, Henrik Toft Sørensen2 and Reimar W Thomsen2, 1Department of Internal Medicine and RECIF, Amiens-Picardie University Hospital, Amiens, France, 2Department of Clinical Epidemiology, Aarhus University and Aarhus University Hospital, Aarhus, Denmark

    Background/Purpose: There is evidence of an increased risk of cardiovascular disease in several autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus. In primary…
  • Abstract Number: 2514 • ACR Convergence 2024

    The Pattern of Renal Involvement in Relapsing Cryoglobulinemic Vasculitis After Successful Sustained Viral Response by Direct-Acting Antiviral Treatments

    Mohamed Tharwat Hegazy1, Ahmed Fayed1 and Gaafar Ragab2, 1Faculty of Medicine, Cairo University, Cairo, Egypt, 2Cairo University, Egypt, Cairo, Egypt

    Background/Purpose: Interferon-free Direct Acting Antiviral (DAA) treatments proved to be effective for the treatment of HCV-induced Cryoglobulinemic Vasculitis (HCV-Cryovas). Some reports showed relapses of HCV-Cryovas…
  • « Previous Page
  • 1
  • …
  • 220
  • 221
  • 222
  • 223
  • 224
  • …
  • 2607
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology